FoxWayne, Aerami Therapeutics SPAC Deal Worth $195M: Report


Blank-check company FoxWayne Enterprises Acquisition is in talks to merge with Aerami Therapeutics Holdings, which develops treatments for severe respiratory diseases, in a deal that’s set to value the combined entity at about $195 million, Bloomberg reports, citing people with knowledge of the matter.

The SPAC executed a non-binding letter of intent with Aerami earlier this month, according to a securities filing, which didn’t disclose the transaction size. A deal is yet to be finalized and terms could still change. Read more.

Related Posts